CellControl Biomedical Laboratories AG
This article was originally published in Start Up
Executive Summary
CellControl Biomedical Laboratories AG hopes oncologists will use its Chemoselect chemosensitivity test before deciding on a course of treatment for a cancer patient. The test can evaluate the effect of four to seven single substances or drug combinations on an individual's tumor cells. The firm is also working to develop cancer therapeutics--specifically an immune-stimulating vaccine against ovarian cancer.